IP Verse

Compositions And Methods For Enhancing Coagulation Factor Viii Function - EP2482841

The patent EP2482841 was granted to The Childrens Hospital OF Philadelphia on Sep 28, 2022. The application was originally filed on Oct 4, 2010 under application number EP10821393A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2482841

THE CHILDRENS HOSPITAL OF PHILADELPHIA
Application Number
EP10821393A
Filing Date
Oct 4, 2010
Status
Patent Maintained As Amended
Aug 26, 2022
Grant Date
Sep 28, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BIOVERATIV THERAPEUTICSAug 21, 2019ZWICKERADMISSIBLE
FH SERVICESAug 21, 2019LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBBADMISSIBLE
STRAWMANAug 16, 2019GILLADMISSIBLE

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2004005670
OPPOSITIONEP0294910
OPPOSITIONEP0295597
OPPOSITIONUS5422260
OPPOSITIONUS5451521
OPPOSITIONUS7041635
OPPOSITIONWO0170968
OPPOSITIONWO03100053
OPPOSITIONWO2004067566
OPPOSITIONWO8800831
OPPOSITIONWO8805825
SEARCHCA2264431

Non-Patent Literature (NPL) Citations (29) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- NICHOLS TC; DILLOW AM; FRANCK HW ET AL., PROTEIN REPLACEMENT THERAPY AND GENE TRANSFER IN CANINE MODELS OF HEMOPHILIA A, HEMOPHILIA B, VON WILLEBRAND DISEASE, AND FACTOR VII-
EXAMINATION- J. I. Siner ET AL, "Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype", Blood, (20130131), vol. 121, no. 21, doi:10.1182/blood-2012-10-464164, ISSN 0006-4971, pages 4396 - 4403, XP055100144
INTERNATIONAL-SEARCH-REPORT- SABATINO, D.E. ET AL., "Recombinant Canine B-Domain Deleted FVIII Exhibits High Specific Activity and is Safe in the Canine Hemophilia A Model.", BLOOD., (20090921), vol. 114, no. 20, pages 4562 - 4565, XP008155594
OPPOSITION- Anonymous, "Thrombosis, Wikipedia the free encyclopedia", (20190723), pages 1 - 13, URL: https://en.wikipedia.org/w/index.php?title=Thrombosis&oldid=907537401-
OPPOSITION- Anonymous, "Thrombosis, Wikipedia the free encyclopedia", (20190723), pages 1 - 13, URL: https://en.wikipedia.org/w/index.php?title=Thrombosis&oldid=907537401, XP055638304-
OPPOSITION- BIHOREAU et al., Biochem. J., (19910000), vol. 277, pages 23 - 31-
OPPOSITION- BIHOREAU et al., "STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF FACTOR VIII-DELTAII, A NEW RECOMBINANT FACTOR VIII LACKING MOST OF THE B-DOMAIN", Biochem. J., (19910000), vol. 277, pages 23 - 31, XP008022185-
OPPOSITION- CAO et al., PNAS, (20080000), vol. 105, no. 21, pages 7416 - 7421-
OPPOSITION- Communication under Article 94(3) EPC dated 2 February 2017-
OPPOSITION- Doering et al. (2004), THE JOURNAL OF BIOLOGICAL CHEMISTRY, 279(8): 6546-6552-
OPPOSITION- DONATH et al., Biochem J, (19950000), vol. 312, pages 49 - 55-
OPPOSITION- Experimental report "Exhibit A” (i.e. Table 1 and Figure 7 of D23)-
OPPOSITION- GOUSE et al., "New Thrombotic Events in Ischemic Stroke Patients with Elevated Factor VIII /Abstract/", Thrombosis, (20141217), vol. 2014-
OPPOSITION- KRISHNAN et al., Eur. J. Biochem., (19910000), vol. 195, pages 637 - 644-
OPPOSITION- LEYTE et al., JOURNAL OF BIOLOGICAL CHEMISTRY, (19910000), vol. 266, no. 2, pages 740 - 746-
OPPOSITION- LEYTE et al., "SULFATION OF TYR 1680 OF HUMAN BLOOD COAGULATION FACTOR VIII IS ESSENTIAL FOR THE INTERACTION OF FACTOR VIII WITH VON WILLEBRAND FACTOR", JOURNAL OF BIOLOGICAL CHEMISTRY, (19910000), vol. 266, no. 2, pages 740 - 746, XP002923546-
OPPOSITION- MEULIEN et al., "A NEW RECOMBINANT PROCOAGULANT PROTEIN DERIVED FROM THE CDNA ENCODING HUMAN FACTOR VIII", Protein Engineering, (19880000), vol. 2, no. 4, pages 301 - 306, XP000023666-
OPPOSITION- MEULIEN et al., Protein Engineering, (19880000), vol. 2, no. 4, pages 301 - 306-
OPPOSITION- Patentee’s response of 11 August 2017 to Communication under Article 94(3)EPC dated 02.02.2017-
OPPOSITION- SABATINO et al., Blood, (20090000), vol. 114, no. 20, pages 4562 - 4565-
OPPOSITION- Sequence alignment between human FVIII and canine (dog) FVIII-
OPPOSITION- Siner et al. (2016), JCI Insight, l(16):e89371, doi: 10.1172/Jci.insight.89371-
OPPOSITION- Spencer et al. (2011), Molecular Therapy, 19(2):302-309, doi:101038/mit. 2010.239-
OPPOSITION- DONATH et al., "Characterization of des-(741-1668)-factor VIII, a single-chain factor VIII variant with a fusion site susceptible to proteolysis by thrombin and factor Xa", Biochem J, (19950000), vol. 312, pages 49 - 55, XP009155492
OPPOSITION- CAO et al., "Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13", PNAS, (20080000), vol. 105, no. 21, pages 7416 - 7421, XP055569884
OPPOSITION- KRISHNAN et al., "Thrombin cleavage analysis of a novel antihaemophilic factor variant, factor VIII dII", Eur. J. Biochem., (19910000), vol. 195, pages 637 - 644, XP002992596
OPPOSITION- SABATINO et al., "Recombinant Canine B-Domain Deleted FVIII Exhibits High Specific Activity and is Safe in the Canine Hemophilia A Model", Blood, (20090000), vol. 114, no. 20, pages 4562 - 4565, XP008155594
SEARCH- SINER JOSHUA I ET AL, "Bioengineering Factor VIII B-Domain Sequences Improves Function and Efficacy in Hemophilia A Models (Abstract 2208)", BLOOD, & 54TH ANNUAL MEETING AND EXPOSITION OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY (ASH); ATLANTA, GA, USA; DECEMBER 08 -11, 2012, (201211), vol. 120, no. 21, XP002696553 [T] * abstract *-
SEARCH- OESTERBERG T ET AL, "B-DOMAIN DELETED RECOMBINANT FACTOR VIII FORMULATION AND STABILITY", SEMINARS IN HEMATOLOGY, PHILADELPHIA, PA, US, (20010401), vol. 38, no. 2, SUPPL. 04, doi:10.1053/SHEM.2001.25892, ISSN 0037-1963, pages 40 - 43, XP009011531 [X] 1 [A] 2-12

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents